Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Müller

Showing results (481-490 of 651) with videos related to

Pageof 66
Sort By:
Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
Blood|July 10, 2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyHartmut Döhner, Michael Lübbert, Walter Fiedler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 30, 2014
Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR ImagingSonja Schelhaas, Lydia Wachsmuth, Thomas Viel, et al.
British Journal of Haematology|March 5, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AMLSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
Leukemia|August 27, 2024
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 studyPatrick Derigs, Maria-Luisa Schubert, Peter Dreger, et al.
Haematologica|June 29, 2023
Clonal hematopoiesis with <i>DNMT3A</i> and <i>PPM1D</i> mutations impairs regeneration in autologous stem cell transplant recipientsPatrick Stelmach, Sarah Richter, Sandra Sauer, et al.
Oncogene|December 8, 2020
NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migrationChunhong Cui, Yi Liu, Dennis Gerloff, et al.
Haematologica|January 20, 2022
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilitiesNicola Giesen, Nagarajan Paramasivam, Umut H Toprak, et al.
Biomedicines|December 24, 2021
Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell LymphomasFranziska Lea Schümann, Elisabeth Groß, Marcus Bauer, et al.
British Journal of Cancer|March 4, 2018
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsAngelique Bruyer, Ken Maes, Laurie Herviou, et al.
Pageof 66

Showing results (481-490 of 651) with videos related to

Sort By:
Pageof 66
Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
Blood|July 10, 2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyHartmut Döhner, Michael Lübbert, Walter Fiedler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 30, 2014
Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR ImagingSonja Schelhaas, Lydia Wachsmuth, Thomas Viel, et al.
British Journal of Haematology|March 5, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AMLSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
Leukemia|August 27, 2024
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 studyPatrick Derigs, Maria-Luisa Schubert, Peter Dreger, et al.
Haematologica|June 29, 2023
Clonal hematopoiesis with <i>DNMT3A</i> and <i>PPM1D</i> mutations impairs regeneration in autologous stem cell transplant recipientsPatrick Stelmach, Sarah Richter, Sandra Sauer, et al.
Oncogene|December 8, 2020
NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migrationChunhong Cui, Yi Liu, Dennis Gerloff, et al.
Haematologica|January 20, 2022
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilitiesNicola Giesen, Nagarajan Paramasivam, Umut H Toprak, et al.
Biomedicines|December 24, 2021
Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell LymphomasFranziska Lea Schümann, Elisabeth Groß, Marcus Bauer, et al.
British Journal of Cancer|March 4, 2018
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsAngelique Bruyer, Ken Maes, Laurie Herviou, et al.
Pageof 66